Everything below concerns Lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-26. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
=== Cancer === Dysregulation of YAP/TAZ-mediated transcriptional activity is implicated in the development of abnormal cell growth and hyperactivation of YAP and TAZ has been observed amongst many cancers. Hence YAP1 represents a potential target for the treatment of cancer. While YAP has been identified as a proto-oncogene, it can also act as a tumor suppressor depending on cellular context.
== Abnormalities == Aspermia: absence of semen Azoospermia: absence of sperm Hypospermia: low semen volume Hyperspermia: high semen volume Oligozoospermia: very low sperm count Asthenozoospermia: poor sperm motility Teratozoospermia: sperm carry more morphological defects than usual Necrozoospermia: all sperm in the ejaculate are dead Leucospermia: a high level of white blood cells in semen
== Research and career == Barran stayed with Stace for three years after completing her PhD in 1998. In 2001 Barran joined the University of California, Santa Barbara, working as a postdoctoral fellow with Mike Bowers. She was interested in the structure and stability of small molecules in the gas phase. She looked at how Ion-mobility spectrometry could be used to identify conformation. Barran joined the University of Edinburgh as an Engineering and Physical Sciences Research Council (EPSRC) Advanced Research Fellow in 2002. In 2005 she was awarded the 10th Desty Memorial prize for her innovations in Separation Science. She was made a Senior Lecturer in 2009. She worked on mass spectrometry techniques that can be used to evaluate conformational change, aggregation and intrinsic conformation. She investigated mass spectrometry for therapeutics for pre-fibrillar aggregation. She helped to establish the Scottish Instrumentation and Resource Centre for Advanced Mass Spectrometry at the University of Edinburgh. This had an initial remit to provide proteomic analysis for the MRC Human Genetics Unit. In 2013 Barran was appointed to the Manchester Institute of Biotechnology as a Chair in Mass Spectrometry sponsored by Waters Corporation. She led an EPSRC platform grant to study the structure-activity relationships of Beta defensins. She works with Cait MacPhee, Garth Cooper and Tilo Kunath on neurodegenerative proteins, and with several groups including Richard Kriwacki, Rohit Pappu and Gary Daughdrill to examine intrinsically disordered proteins.
Commission E2: Heat Pumps and Energy Recovery Commission members are proposed by member countries, then appointed by the STC following proposals from the Presidents of commissions. These commission members comprise industry, university, and research centre specialists or refrigeration practitioners. The aim of "Commission E2: Heat Pumps and Energy Recovery" is to promote and enhance scientific and technological knowledge in heat pump and energy recovery fields, thanks to various activities such as the organisation or co-sponsoring of international conferences, or the publication of books and Informatory Notes.
Sources: en.wikipedia.org
11B Infantryman (includes soldiers formerly designated 11M [Mechanized] and 11H [Anti-armor]) 11B Infantryman is the basic infantry soldier MOS of the US Army. 11C Indirect Fire Infantryman (Mortarman) 11X Undetermined Infantry (Open Enlistment Option, B/C determined during training.) 11Z Infantry Senior Sergeant
Side effects of enasidenib included nausea, diarrhea, elevated bilirubin and, most notably, differentiation syndrome. Glutaminase (GLS), the enzyme responsible for converting glutamine to glutamate via hydrolytic deamidation during the first reaction of glutaminolysis, can also be targeted. In recent years, many small molecules, such as azaserine, acivicin, and CB-839 have been shown to inhibit glutaminase, thus reducing cancer cell viability and inducing apoptosis in cancer cells. Due to its effective antitumor ability in several cancer types such as ovarian, breast and lung cancers, CB-839 is the only GLS inhibitor currently undergoing clinical studies for FDA-approval.
=== Prominent people with this condition === Danny DeVito, American actor, producer, and director Robert Reich, former United States Secretary of Labor under President Bill Clinton from 1993 to 1997 David Wetherill, British Paralympian table tennis athlete
== Mechanism == The main function of the SEC23A protein is to hydrolyze or break down a guanosine triphosphate (GTP) molecule bound to the SAR1A protein at the start of the COPII pathway. The energy released from the breaking of the GTP bond provides energy necessary to undergo another reaction. This triggers uncoating of the vesicle (a membrane bound carrying compartment for molecules) containing a secretory protein destined for packaging in the Golgi apparatus of the cell. Uncoating the vesicle exposes SNARE proteins which are needed for the vesicle to bind to the membrane site on the endoplasmic reticulum. A mutation in the SEC23A gene prevents the vesicle from uncoating so it will not bind to the receptor site on the endoplasmic reticulum to be released into the cytoplasm for transport to the Golgi apparatus. Thus, the vesicles will accumulate in the endoplasmic reticulum, causing it to become enlarged or distended. Ultimately, this causes the craniofacial symptoms present in patients with CLSD. This is probably due to abnormal secretion of collagen and possibly other secretory proteins which have accumulated in the endoplasmic reticulum. Collagen is responsible to for skull ossification, among other things.
First, the ancient tanners would soak the skins in water to clean and soften them. Then they would pound and scour the skin to remove any remaining flesh and fat. Hair was removed by soaking the skin in urine, painting it with an alkaline lime mixture, or simply allowing the skin to putrefy for several months then dipping it in a salt solution. After the hair was loosened, the tanners scraped it off with a knife. Once the hair was removed, the tanners would "bate" (soften) the material by pounding dung into the skin, or soaking the skin in a solution of animal brains. Bating was a fermentative process that relied on enzymes produced by bacteria found in the dung. Among the kinds of dung commonly used were those of dogs or pigeons. Historically the actual tanning process used vegetable tanning. In some variations of the process, cedar oil, alum, or tannin was applied to the skin as a tanning agent. As the skin was stretched, it would lose moisture and absorb the agent. Following the adoption in medicine of soaking gut sutures in a chromium (III) solution after 1840, it was discovered that this method could also be used with leather and thus was adopted by tanners.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.